SUMMARY
This is the first prospective study showing 12-month durability of results from RF microneedling for GSM, supporting Morpheus8V as a long-term alternative to hormonal therapies. Conducted across multiple U.S. centers from 2021–2024, data from 21–23 participants were included in the final 12-month review. The study concluded that RF microneedling delivered by the Morpheus8V applicator is safe and that RF ablation up to 3mm is an effective therapy for GSM with durability to 12 months. An added advantage may be a significant improvement in bladder dysfunction.
TOPICS COVERED
KEY FINDINGS
- VHIS: sustained improvement at 3, 6, and 12 months (from 11.7 to 18.8, p < 0.001)
- Urinary symptoms (UDI-6): significant improvement sustained through 12 months
- Sexual function (FSFI): improved up to 6 months; slight decline by 12 months, suggesting possible need for maintenance treatments
- Pain: very low VAS scores (1.6–1.9)
- No adverse events reported
